Histone deacetylase inhibitors
US8420698B2 · kind B2 · utility
12Cited by
143References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 23, 2010 |
| Grant date | Apr 16, 2013 |
| Priority date | — |
| Expiry date | Dec 23, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D307/54
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.